Search Results - "Visser, Brendan C"

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA by Scherer, Florian, Kurtz, David M, Newman, Aaron M, Stehr, Henning, Craig, Alexander F M, Esfahani, Mohammad Shahrokh, Lovejoy, Alexander F, Chabon, Jacob J, Klass, Daniel M, Liu, Chih Long, Zhou, Li, Glover, Cynthia, Visser, Brendan C, Poultsides, George A, Advani, Ranjana H, Maeda, Lauren S, Gupta, Neel K, Levy, Ronald, Ohgami, Robert S, Kunder, Christian A, Diehn, Maximilian, Alizadeh, Ash A

“…Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains…”
Get more information

The First Decade of Laparoscopic Pancreaticoduodenectomy in the United States: Costs and Outcomes Using the Nationwide Inpatient Sample by Tran, Thuy B., Dua, Monica M., Worhunsky, David J., Poultsides, George A., Norton, Jeffrey A., Visser, Brendan C.

“…Background Minimally invasive pancreaticoduodenectomy (PD) remains an uncommon procedure, and the safety and efficacy remain uncertain beyond single…”
Get full text

Does the Extent of Resection Impact Survival for Duodenal Adenocarcinoma? Analysis of 1,611 Cases by Cloyd, Jordan M., Norton, Jeffrey A., Visser, Brendan C., Poultsides, George A.

“…Background Because duodenal adenocarcinoma (DA) is relatively rare, few studies have investigated the impact of resection type on long-term outcomes. Methods…”
Get full text

Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity by Pollom, Erqi L., MD, Alagappan, Muthuraman, BS, von Eyben, Rie, MS, Kunz, Pamela L., MD, Fisher, George A., MD, Ford, James A., MD, Poultsides, George A., MD, Visser, Brendan C., MD, Norton, Jeffrey A., MD, Kamaya, Aya, MD, Cox, Veronica L., MD, Columbo, Laurie A., RN, Koong, Albert C., MD, PhD, Chang, Daniel T., MD

“…Purpose We report updated outcomes of single- versus multifraction stereotactic body radiation therapy (SBRT) for unresectable pancreatic adenocarcinoma…”
Get full text

Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors by Krampitz, Geoffrey Wayne, George, Benson M., Willingham, Stephen B., Volkmer, Jens-Peter, Weiskopf, Kipp, Jahchan, Nadine, Newman, Aaron M., Sahoo, Debashis, Zemek, Allison J., Yanovsky, Rebecca L., Nguyen, Julia K., Schnorr, Peter J., Mazur, Pawel K., Sage, Julien, Longacre, Teri A., Visser, Brendan C., Poultsides, George A., Norton, Jeffrey A., Weissman, Irving L.

“…Pancreatic neuroendocrine tumors (PanNETs) are a type of pancreatic cancer with limited therapeutic options. Consequently, most patients with advanced disease…”
Get full text

Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors by Squires, Malcolm H., Worth, Patrick J., Konda, Bhavana, Shah, Manisha H., Dillhoff, Mary E., Abdel-Misih, Sherif, Norton, Jeffrey A., Visser, Brendan C., Dua, Monica, Pawlik, Timothy M., Schmidt, Carl R., Poultsides, George, Cloyd, Jordan M.

“…The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors…”
Get full text

Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis by Cloyd, Jordan M., MD, Kopecky, Kimberly E., MD, Norton, Jeffrey A., MD, Kunz, Pamela L., MD, Fisher, George A., MD, Visser, Brendan C., MD, Dua, Monica M., MD, Park, Walter G., MD, MS, Poultsides, George A., MD

“…Background Although most pancreatic neuroendocrine tumors are solid, approximately 10% are cystic. Some studies have suggested that cystic pancreatic…”
Get full text

Management of Postoperative Hepatic Failure by Qadan, Motaz, MD, PhD, Garden, O. James, CBE, MD, FACS (Hon), Corvera, Carlos U., MD, FACS, Visser, Brendan C., MD, FACS

Get full text

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer by Kidess-Sigal, Evelyn, Liu, Haiyan E, Triboulet, Melanie M, Che, James, Ramani, Vishnu C, Visser, Brendan C, Poultsides, George A, Longacre, Teri A, Marziali, Andre, Vysotskaia, Valentina, Wiggin, Matthew, Heirich, Kyra, Hanft, Violet, Keilholz, Ulrich, Tinhofer, Ingeborg, Norton, Jeffrey A, Lee, Mark, Sollier-Christen, Elodie, Jeffrey, Stefanie S

“…Treatment of advanced colorectal cancer (CRC) requires multimodal therapeutic approaches and need for monitoring tumor plasticity. Liquid biopsy biomarkers,…”
Get full text

Duodenal adenocarcinoma: Advances in diagnosis and surgical management by Cloyd, Jordan M, George, Elizabeth, Visser, Brendan C

“…Duodenal adenocarcinoma is a rare but aggressive malignancy. Given its rarity, previous studies have traditionally combined duodenal adenocarcinoma (DA) with…”
Get full text

Laparoscopic Transgastric Necrosectomy for the Management of Pancreatic Necrosis by Worhunsky, David J., MD, Qadan, Motaz, MD, PhD, Dua, Monica M., MD, Park, Walter G., MD, Poultsides, George A., MD, FACS, Norton, Jeffrey A., MD, FACS, Visser, Brendan C., MD, FACS

“…Background Traditional open necrosectomy for pancreatic necrosis is associated with significant morbidity and mortality. Although minimally invasive techniques…”
Get full text

Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma by Tran, Thuy B., MD, Qadan, Motaz, MD, Dua, Monica M., MD, Norton, Jeffrey A., MD, Poultsides, George A., MD, Visser, Brendan C., MD

“…Background Nodal metastasis is a known prognostic factor for small bowel adenocarcinoma. The goals of this study were to evaluate the number of lymph nodes…”
Get full text

Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine by Park, Walter G., MD, Wu, Manhong, PhD, Bowen, Raffick, PhD, Zheng, Ming, PhD, Fitch, William L., PhD, Pai, Reetesh K., MD, Wodziak, Dariusz, BS, Visser, Brendan C., MD, Poultsides, George A., MD, Norton, Jeff A., MD, PhD, Banerjee, Subhas, MD, Chen, Ann M., MD, Friedland, Shai, MD, Scott, Brennan A., MD, Pasricha, Pankaj Jay, MD, Lowe, Anson W., MD, Peltz, Gary, MD, PhD

“…Background Better pancreatic cyst fluid biomarkers are needed. Objective To determine whether metabolomic profiling of pancreatic cyst fluid would yield…”
Get full text

Laparoscopic hepatectomy in cirrhotics: safe if you adjust technique by Worhunsky, David J., Dua, Monica M., Tran, Thuy B., Siu, Bernard, Poultsides, George A., Norton, Jeffrey A., Visser, Brendan C.

“…Background Minimally invasive liver surgery is a growing field, and a small number of recent reports have suggested that laparoscopic liver resection (LLR) is…”
Get full text

Postoperative Serum Amylase Predicts Pancreatic Fistula Formation Following Pancreaticoduodenectomy by Cloyd, Jordan M., Kastenberg, Zachary J., Visser, Brendan C., Poultsides, George A., Norton, Jeffrey A.

“…Introduction Early identification of patients at risk for developing pancreatic fistula (PF) after pancreaticoduodenectomy (PD) may facilitate prevention or…”
Get full text

Characterization of Cystic Pancreatic Masses: Relative Accuracy of CT and MRI by Visser, Brendan C, Yeh, Benjamin M, Qayyum, Aliya, Way, Lawrence W, McCulloch, Charles E, Coakley, Fergus V

“…The objective of our study was to determine the role and relative accuracy of CT and MRI in the characterization of cystic pancreatic masses. We…”
Get full text

Laparoscopic Spleen-Preserving Distal Pancreatectomy: The Technique Must Suit the Lesion by Worhunsky, David J., Zak, Yulia, Dua, Monica M., Poultsides, George A., Norton, Jeffrey A., Visser, Brendan C.

“…Splenic preservation is currently recommended during minimally invasive surgery for benign tumors of the distal pancreas. The aim of this study was to evaluate…”
Get full text

An economic analysis of pancreaticoduodenectomy: should costs drive consumer decisions? by Tran, Thuy B., M.D, Dua, Monica M., M.D, Worhunsky, David J., M.D, Poultsides, George A., M.D, Norton, Jeffrey A., M.D, Visser, Brendan C., M.D

“…Abstract Background Consumer groups campaign for cost transparency believing that patients will select hospitals accordingly. We sought to determine whether…”
Get full text

Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors by Titan, Ashley L, Norton, Jeffrey A, Fisher, Andrea T, Foster, Deshka S, Harris, E John, Worhunsky, David J, Worth, Patrick J, Dua, Monica M, Visser, Brendan C, Poultsides, George A, Longaker, Michael T, Jensen, Robert T

“…Although outcome of surgical resection of liver metastases from pancreatic neuroendocrine tumors (PNETs) has been extensively studied, little is known about…”
Get full text

Establishment and Application of a Novel Difficulty Scoring System for da Vinci Robotic Pancreatoduodenectomy by Sun, Hongfa, Sun, Chuandong, Zhang, Bingyuan, Ma, Kai, Wu, Zehua, Visser, Brendan C., Han, Bing

“…Background Robotic pancreatoduodenectomy (RPD) technology is developing rapidly, but there is still a lack of a specific and objective difficulty evaluation…”
Get full text